2009-11-10 15:51:08 -

Fero Industries, Inc. (OTCBB: FROI) (the “Company”) is pleased to announce to the appointment of Robert C. Moellering, Jr., M.D. as Chairman of the Scientific Advisory Board of Pyro Pharmaceuticals, Inc.

As previously announced, the Company has executed a share exchange agreement with Pyro Pharmaceuticals, Inc. for the acquisition of Pyro through an exchange of Pyro’s capital stock for shares of the Company’s common stock, with Fero remaining as the parent entity and Pyro as a subsidiary. The acquisition of Pyro is expected to close by November 30, 2009. The closing is subject to satisfaction of certain conditions, including the requisite approval of Pyro’s shareholders and procurement of financing.

Robert C. Moellering, Jr., M.D., is the Shields Warren-Mallinckrodt Professor of Medical

Research, Harvard Medical School, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Dr. Moellering is a consult and member of the scientific advisory boards of major pharmaceutical and biotechnology companies including Merck, Glaxo, Vertex, Chiron, Abbott, Bristol Myers Squibb, Rhone-Poulenc Rorer, and Hoechst Marion Roussel. He is on the editorial board of most of the clinical and infectious disease journals and a member of numerous national and international infectious disease committees. Dr. Moellering was a Research Fellow in Infectious Disease, Department of Medicine, Massachusetts General Hospital and was a Clinical Fellow in Infectious Disease, Department of Medicine, Massachusetts General Hospital. He received an M.D. from the Harvard Medical School a B.A. in Zoology from Valparaiso University.

Dr. Moellering said: “antimicrobial resistance is a rapidly growing threat to human health and welfare. At a time when we desperately need new antibiotics to fight these resistant pathogens, the developmental pipeline is drying up as fewer and fewer new agents are identified and brought to clinical utility. Pyro's techniques allow the identification of a number of unique enzymatic targets in bacteria and should be the basis for much-needed new agents active against resistant pathogens. In view of this, I am pleased to serve as Chairman of the new Pyro Scientific Advisory Board.”

Alan M. Schechter, Chairman and CEO of Pyro Pharmaceuticals, Inc, added.

“Dr. Moellering is a world-renown clinician and researcher in infectious diseases. His agreement to be the Chairman of the Pyro’s Scientific Advisory Board should assist Pyro to chart a research, development, and clinical strategy that we expect will put us on a path to success. On behalf of Pyro, we welcome Dr. Moellering’s scientific and clinical stewardship, as we work towards the development of a new class of antibiotics.”

About Pyro Pharmaceuticals, Inc.

Pyro Pharmaceuticals, Inc. is a developmental stage drug research and development company. Pyro’s goal is to identify, evaluate, develop and acquire new promising antibiotic therapeutic treatments against multi-drug resistant infectious microorganisms in humans.

Pyro is a development stage company and currently does not have any new product candidate antibiotics developed, nor are any product candidates under development. Its plans and businesses are “proposed” and “intended,” but it may not be able to successfully implement them with without funding. In addition, Pyro has not earned revenues and has incurred losses since its incorporation. As a development stage company, Pyro’s prospects are subject to all of the risks, expenses, and uncertainties frequently encountered by companies in the drug development and pharmaceutical business.

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by the use of words such as "anticipate," "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "intend," and similar expressions. Such forward-looking statements, involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Fero Industries, Inc. (the Company) to be materially different from those expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including but not limited to the Company's ability to: (i) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; (iv) other risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission, which are available for review at www.sec.gov : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww .. under "Search for Company Filings," and (v) risk factors to be disclosed in a Current Report on Form 8-K that the Company intends to file upon the closing of the acquisition of Pyro Pharmaceuticals, Inc. There can be no assurance that the Company will complete the acquisition of Pyro Pharmaceuticals, Inc.

For more information visit Pyro’s website at www.pyropharmaceuticals.com : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww .. or contact Michael Irving at Interactive Resources Group, Inc. at 1-866-998-9669 Ext.150

For Fero Industries, Inc.Interactive Resources Group, Inc.Michael

Irving, 1-866-998-9669 Ext.150